Ergoteles’s AdaptHealth AHCO Stock Holding History

Ergoteles’s Portfolio AHCO Stock Details AHCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-77,670	Closed	-$1.49M	–	1208
2022 Q4	$1.49M	Buy	+77,670	New	+$1.64M	0.05%	351
2022 Q2	–	Sell	-36,670	Closed	-$588K	–	1607
2022 Q1	$588K	Buy	+36,670	New	+$659K	0.02%	611
2021 Q4	–	Sell	-38,300	Closed	-$892K	–	1208
2021 Q3	$892K	Buy	+38,300	New	+$926K	0.03%	409

Other funds holding AHCO

OCA

OEP Capital Advisors New York $194M AUM 9.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SkyKnight Capital San Francisco, California $107M AUM 9.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ergoteles's AHCO Position: Q1 2023 in Review

Ergoteles sold out of AdaptHealth (AHCO) in Q1 2023, closing a stake of 77,670 shares — an estimated $1.49M sold.

Ergoteles first reported a position in AHCO in Q3 2021 and held it in 3 quarters. The position peaked at $1.49M in Q4 2022. 172 funds tracked by Wall St. Rank hold AHCO as of Q1 2023.

Ergoteles reported no remaining AdaptHealth position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 77,670 AdaptHealth shares in Q1 2023, an estimated $1.49M.
Ergoteles first reported a position in AdaptHealth in Q3 2021 and held it in 3 quarters.
Ergoteles's AdaptHealth position peaked at $1.49M in Q4 2022.
172 funds tracked by Wall St. Rank held AdaptHealth as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.